Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Kura Oncology (KURA) EBITDA: 2024-2025

Historic EBITDA for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to -$80.0 million.

  • Kura Oncology's EBITDA fell 51.44% to -$80.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$236.9 million, marking a year-over-year change of. This contributed to the annual value of -$171.9 million for FY2024, which is 17.88% down from last year.
  • As of Q3 2025, Kura Oncology's EBITDA stood at -$80.0 million, which was down 10.09% from -$72.7 million recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's EBITDA ranged from a high of -$19.6 million in Q4 2024 and a low of -$80.0 million during Q3 2025.
  • Moreover, its 2-year median value for EBITDA was -$52.8 million (2024), whereas its average is -$55.6 million.
  • Data for Kura Oncology's EBITDA shows a maximum YoY slumped of 51.44% (in 2025) over the last 5 years.
  • Kura Oncology's EBITDA (Quarterly) stood at -$19.6 million in 2024, then crashed by 51.44% to -$80.0 million in 2025.
  • Its EBITDA stands at -$80.0 million for Q3 2025, versus -$72.7 million for Q2 2025 and -$64.7 million for Q1 2025.